# NexImmune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neximmune

- Industry: Biotechnology
- Headquarters: Gaithersburg, US
- Website: www.neximmune.com
- Latest round: Series A (Jul 1, 2018)
- Investors on record: 1

## About

Founded in 2011 and based in Maryland, US, NexImmune, Inc. is a biotechnology company that develops T cell immunotherapies based on its AIM (artificial immune modulation) technology. SVP Mathias Oelke co-founded the company and was managed by CEO Scott Carmer since 2014. NexImmune, Inc. has four venture rounds from private equity investors, including Amgen Ventures, New Enterprise Associates, and Pfizer Venture Investments. In February 2021, NexImmune, Inc. has listed for an IPO (Initial Public Offering) on the Nasdaq under the ticker symbol NEXI.

NexImmune, Inc.'s R&D team provides AIM technology that enables the development of ACT (adoptive cellular therapy) products manufactured by AIM nanoparticles designed to mimic natural immune functions antigen-presenting cells and treat cancer, infectious disease, and autoimmune disorders. The company's pipeline includes NEXi-001, NEXI-002, and injectable AIM.

## Funding rounds

- Series A, Jul 1, 2018 — Rapha Capital Management

## Investors

- Rapha Capital Management (https://capitalatlas.ai/funds/rapha-capital-management) — Series A